Bone cancer pain: From mechanism to therapy

Current Opinion in Supportive and Palliative Care

Volumn 8, Issue 2, 2014, Pages 83-90

  Mantyh, Patrick W ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Metastasis; Nerve sprouting; Pain; Stromal cells; Tumor

Indexed keywords

ACIDOSIS; ANIMAL; BONE TUMOR; CELL GROWTH; COMPLICATION; DISEASE COURSE; FRACTURE; HUMAN; PAIN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY; SECONDARY; SENSORY NERVE; SENSORY NERVE CELL; STROMA CELL;

ACIDOSIS; AFFERENT PATHWAYS; ANIMALS; BONE NEOPLASMS; CELL GROWTH PROCESSES; DISEASE PROGRESSION; FRACTURES, BONE; HUMANS; PAIN; PALLIATIVE CARE; SENSORY RECEPTOR CELLS; STROMAL CELLS;

EID: 84905821671     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000048     Document Type: Review

References (56)

1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12 (20 Pt 2):6243s-6249s.
2. Dy SM, Asch SM, Naeim A, et al. Evidence-based standards for cancer pain management. J Clin Oncol 2008; 26:3879-3885.
3. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69:1-18.
4. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80 (8 Suppl):1588-1594.
5. Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer 2008; 98:1736-1740.
6. Mercadante S, Villari P, Ferrrera P, Casuccio A. Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage 2004; 28:505-510.
7. Mercadante S, Fulfaro F. Management of painful bone metastases. Curr Opin Oncol 2007; 19:308-314.
8. Cherny N. New strategies in opioid therapy for cancer pain. J Oncol Manage 2000; 9:8-15.
9. Reid CM, Gooberman-Hill R, Hanks GW. Opioid analgesics for cancer pain: symptom control for the living or comfort for the dying? A qualitative study to investigate the factors influencing the decision to accept morphine for pain caused by cancer. Ann Oncol 2008; 19:44-48.
10. Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist 2004; 9:571-591.
11. Weber M, Huber C. Documentation of severe pain, opioid doses, and opioidrelated side effects in outpatients with cancer: a retrospective study. J Pain Symptom Manage 1999; 17:49-54.
12. Harris JD. Management of expected and unexpected opioid-related side effects. Clin J Pain 2008; 24 (Suppl 10):S8-S13.
13. Zylka MJ, Rice FL, Anderson DJ. Topographically distinct epidermal nociceptive circuits revealed by axonal tracers targeted to Mrgprd. Neuron 2005; 45:17-25.
14. Jimenez-Andrade JM, MantyhWG, Bloom AP, et al. A phenotypically restricted set of primary afferent nerve fibers innervate the bone versus skin: therapeutic opportunity for treating skeletal pain. Bone 2010; 46:306-313.
15. Liu Y, Ma Q. Generation of somatic sensory neuron diversity and implications on sensory coding. Curr Opin Neurobiol 2011; 21:52-60.
16. Lopes C, Liu Z, Xu Y, Ma Q. Tlx3 and Runx1 act in combination to coordinate the development of a cohort of nociceptors, thermoceptors, and pruriceptors. J Neurosci 2012; 32:9706-9715.
17. Clohisy DR, Perkins SL, Ramnaraine ML. Review of cellular mechanisms of tumor osteolysis. Clin Orthop Relat Res 2000; 373:104-114.
18. Honore P, Rogers SD, Schwei MJ, et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000; 98: 585-598.
19. Honore P, Mantyh PW. Bone cancer pain: from mechanism to model to therapy. Pain Med 2000; 1:303-309.
20. Horton A, Nesbitt SA, Bennett JH, et al. Integrins and other cell surface attachment molecules of bone cells. In: RG, Raisz LG, editors. Principles of bone biology. San Diego: Academic Press; 2002. pp. 265-286.
21. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88 (12 Suppl):2961-2978.
22. Clezardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005; 65: 4971-4974.
23. Lipton A, Jun S. RANKL inhibition in the treatment of bone metastases. Curr Opin Support Palliat Care 2008; 2:197-203.
24. Honore P, Sabino LN, Schwei MA, et al. Osteoprotegerin blocks bone cancerinduced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nature Med 2000; 6:521-528.
25. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29:1125-1132.
26. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28:5132-5139.
27. von Moos R, Strasser F, Gillessen S, Zaugg K. Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Support Care Cancer 2008; 16:1105-1115.
28. Arrington SA, Schoonmaker JE, Damron TA, et al. Temporal changes in bone mass and mechanical properties in a murine model of tumor osteolysis. Bone 2006; 38:359-367.
29. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nature Rev Cancer 2009; 9:239-252.
30. Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 2006; 7:797-809.
31. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001; 413:203-210.
32. Gould HJ 3rd, Gould TN, England JD, et al. A possible role for nerve growth factor in the augmentation of sodium channels in models of chronic pain. Brain Res 2000; 854:19-29.
33. Ji RR, Samad TA, Jin SX, et al. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002; 36:57-68.
34. Heumann R, Lindholm D, Bandtlow C, et al. Differential regulation of mRNA encoding nerve growth factor and its receptor in rat sciatic nerve during development, degeneration, and regeneration: role of macrophages. Proc Natl Acad Sci U S A 1987; 84:8735-8739.
35. Heumann R, Korsching S, Bandtlow C, Thoenen H. Changes of nerve growth factor synthesis in nonneuronal cells in response to sciatic nerve transection. J Cell Biol 1987; 104:1623-1631.
36. Obata K, Tsujino H, Yamanaka H, et al. Expression of neurotrophic factors in the dorsal root ganglion in a rat model of lumbar disc herniation. Pain 2002; 99:121-132.
37. Halvorson KG, Kubota K, Sevcik MA, et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 2005; 65:9426-9435.
38. Sevcik MA, Ghildardi JR, Peters CM, et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 2005; 115:128-141.
39. Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 2006; 29:507-538.
40. Vega JA, Garcia-Suarez O, Hannestad J, et al. Neurotrophins and the immune system. J Anat 2003; 203:1-19.
41. Ohtori S, Inoue G, Koshi T, et al. Characteristics of sensory neurons innervating the lumbar vertebral body in rats. J Pain 2007; 8:483-488.
42. Schaible HG. Mechanisms of chronic pain in osteoarthritis. Curr Rheumatol Rep 2012; 14:549-556.
43. Bloom AP, Jimenez-Andrade JM, Taylor RN, et al. Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers. J Pain 2011; 12:698-711.
44. Jimenez-Andrade JM, Bloom AP, Stake JI, et al. Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. J Neurosci 2010; 30:14649-14656.
45. Mantyh WG, Jimenez-Andrade JM, Stake JI, et al. Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain. Neuroscience 2010; 171:588-598.
46. Ghilardi JR, Freeman KT, Jimenez-Andrade JM, et al. Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint. Arthritis Rheum 2012; 64:2223-2232.
47. Elitt CM, McIlwrath SL, Lawson JJ, et al. Artemin overexpression in skin enhances expression of TRPV1 and TRPA1 in cutaneous sensory neurons and leads to behavioral sensitivity to heat and cold. J Neurosci 2006; 26:8578-8587.
48. Schweizerhof M, StÖsser S, Kurejova M, et al. Hematopoetic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nature Med 2009; 15:802-807.
49. Carey K. Anti-nerve growth factor drugs exonerated. Nature Biotechnol 2012; 30:298.
50. Holmes D. Anti-NGF painkillers back on track? Nat Rev Drug Discov 2012; 11:337-338.
51. Kumar V, Mahal BA. NGF: the TrkA to successful pain treatment. J Pain Res 2012; 5:279-287.
52. McKelvey L, Shorten GD, O'Keeffe GW. Nerve growth factormediated regulation of pain signalling and proposed new intervention strategies in clinical pain management. J Neurochem 2013; 124:276-289.
53. Gordon-Williams RM, Dickenson AH. Central neuronal mechanisms in cancer-induced bone pain. Curr Opin Support Palliat Care 2007; 1: 6-10.
54. Schwei MJ, Honore P, Rogers SD, et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999; 19:10886-10897.
55. Yanagisawa Y, Furue H, Kawamata F, et al. Bone cancer induces a unique central sensitization through synaptic changes in a wide area of the spinal cord. Mol Pain 2010; 6:38-51.
56. Urch CE, Donovan-Rodriguez T, Dickenson AH. Alterations in dorsal horn neurones in a rat model of cancer-induced bone pain. Pain 2003; 106:347-356.